Systematic Approach for the Formulation and Optimization of Solid Lipid Nanoparticles of Efavirenz by High Pressure Homogenization Using Design of Experiments for Brain Targeting and Enhanced Bioavailability

Table 1

Selection of surfactant on the basis of particle size, PDI and Entrapment Efficiency expressed as mean ± SD () # indicates statistical significance (), PDI: Polydispersity .

S. number	Lipid	Surfactant; (1% w/w)	Particle; (nm)		Entrapment; (%)
1	Tripalmitin	Poloxamer 188	566.4 ± 7.4^#	0.494 ± 0.2	23.93 ± 0.31
		(Pluronic F68)
2	Tripalmitin	Poloxamer 407
		(Pluronic F127)
3	Tripalmitin	Poloxamer 245
		(Pluronic P 85)
4	Tripalmitin	Polysorbate 20
5	Tripalmitin	Polysorbate 60
6	Tripalmitin	Polysorbate 80